NSE · GRANULES.NS
Granules India Limited
₹841.60+₹4.25 (+0.51%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.93% below the high.
Loading market information…
NSE · SUPRIYA.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Supriya Lifescience Limited’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Supriya Lifescience Limited’s forward annual dividend is ₹1.00 per share, paid annual. The forward yield is 0.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Supriya Lifescience Limited’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of ₹5.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Supriya Lifescience Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₹6.30 |
| ₹1.84B-4.01% vs estimate |
| Q3 2025 | Jan 24, 2025 | ₹3.70 | ₹1.40B-18.26% vs estimate |
|---|
| Q2 2025 | Oct 28, 2024 | ₹5.70 | ₹1.66B-1.19% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹841.60+₹4.25 (+0.51%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.93% below the high.
₹1,425.40+₹28.00 (+2.0%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.9% below the high.
₹886.75-₹40.90 (-4.41%)
Aarti Pharmalabs Limited’s quoted price sits in the upper half of its reported 52-week range, 11.58% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹178.77-₹6.16 (-3.33%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 19.92% below the high.
₹363.05-₹46.75 (-11.41%)
Ind-Swift Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 14.51% below the high.
₹212.26+₹7.86 (+3.85%)
Hikal Limited’s quoted price sits in the upper half of its reported 52-week range, 18.67% below the high.
₹240.45-₹11.55 (-4.58%)
Kopran Limited’s quoted price sits in the upper half of its reported 52-week range, 18.72% below the high.
